Objective:

To evaluate the predictive capability of ctDNA assays in renal cell carcinoma patients treated with adjuvant pembrolizumab in the KEYNOTE-564 trial.

Approach:

• Study Overview: Analysis of ctDNA status in participants of the KEYNOTE-564 trial to assess its predictive capability.

Key Findings:

• ctDNA+ status was associated with worse disease-free outcomes.
• Sensitivity of the ctDNA assay was low.

Interpretation:

The findings indicate limitations in the predictive capability of ctDNA assays for this patient population.

Conclusion:

The study highlights the need for improved predictive tools in renal cell carcinoma treatment.